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Background: Neuropsychiatric lupus (NPSLE) can be one of the earliest clinical manifestations in human lupus.
However, its mechanisms are not fully understood. In lupus, a compromised blood-brain barrier may allow for the
passage of circulating autoantibodies into the brain, where they can induce neuropsychiatric abnormalities
including depression-like behavior and cognitive abnormalities. The purpose of this study was to determine the role
of B cells and/or autoantibodies in the pathogenesis of murine NPSLE.
Methods: We evaluated neuropsychiatric manifestations, brain pathology, and cytokine expression in constitutively
(JhD/MRL/lpr) and conditionally (hCD20-DTA/MRL/lpr, inducible by tamoxifen) B cell-depleted mice as compared to
MRL/lpr lupus mice.
Results: We found that autoantibody levels were negligible (JhD/MRL/lpr) or significantly reduced (hCD20-DTA/
MRL/lpr) in the serum and cerebrospinal fluid, respectively. Nevertheless, both JhD/MRL/lpr and hCD20-DTA/MRL/
lpr mice showed profound depression-like behavior, which was no different from MRL/lpr mice. Cognitive deficits
were also observed in both JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice, similar to those exhibited by MRL/lpr mice.
Furthermore, although some differences were dependent on the timing of depletion, central features of NPSLE in
the MRL/lpr strain including increased blood-brain barrier permeability, brain cell apoptosis, and upregulated
cytokine expression persisted in B cell-deficient and B cell-depleted mice.
Conclusions: Our study surprisingly found that B cells and/or autoantibodies are not required for key features of
neuropsychiatric disease in murine NPSLE.
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Neuropsychiatric lupus (NPSLE) is a debilitating mani-
festation of systemic lupus erythematous (SLE), with a
prevalence of approximately 40 % [1]. NPSLE manifesta-
tions include a broad spectrum of syndromes; headache,
mood disorders, cognitive dysfunction, seizures, cerebro-
vascular diseases, and anxiety are the most common [2].
The pathogenesis of NPSLE is believed to be dependent
upon whether the symptoms are focal or diffuse. Often,* Correspondence: chaim.putterman@einstein.yu.edu
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are associated with anti-phospholipid antibody-related
hypercoagulability and thrombosis, while diffuse deficits,
including depression and cognitive impairment, are
mediated by as of yet unclear inflammatory pathways
[3]. NPSLE can occur at any stage of disease [4]. The
treatment options available are limited, with most pa-
tients treated empirically with immunosuppressive
agents, corticosteroids, or symptomatic therapy [3].
The mechanisms underlying diffuse NPSLE develop-
ment are not well understood; however, autoantibody-
mediated brain damage and cytokine-induced CNS
inflammation are believed to be important [5]. To date,
several studies have examined whether specific subtypesdistributed under the terms of the Creative Commons Attribution 4.0
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can serve as biomarkers) of NPSLE. A role for anti-
ribosomal P and anti-NMDA receptor autoantibodies in
NPSLE has been proposed, but biomarker studies have
not been entirely consistent [6]. Furthermore, while
rituximab, an anti-CD20 monoclonal antibody used to
deplete B cells in antibody-mediated diseases has shown
some promise [7], a recent systematic review concluded
that the evidence to date supporting its use in human
NPSLE is relatively weak [8].
The MRL/lpr mouse strain is a validated murine lupus
model, used extensively in the study of NPSLE [9]. Aside
from the peripheral features such as autoantibody upreg-
ulation and severe kidney pathology, this strain also
manifests cognitive deficits and depression-like behavior
mimicking those found in human NPSLE [9]. Moreover,
MRL/lpr mice exhibit an earlier onset of disease com-
pared to NZB/W F1 and BXSB, and is one of the murine
lupus strains with a greater prevalence of disease in
females [9].
In order to investigate the potential role of B cells and
autoantibodies in NPSLE, we utilized a B cell depletion
strategy in MRL/lpr mice. A previous study examined
the efficacy of rituximab in the MRL/lpr strain and
found that B cell depletion was difficult to achieve,
though after prolonged treatment, nephritis was amelio-
rated; however, NPSLE was not evaluated [10]. Since
antibody-mediated cell depletion is markedly impaired
in lupus [10], we employed a genetic approach to assess
the roles of B cells in NPSLE manifestations, using con-
stitutively deficient (JhD/MRL/lpr) and conditionally B
cell-depleted (hCD20-DTA/MRL/lpr) lupus-prone mice.Methods
Mice
JhD/MRL/lpr mice were generated as described previ-
ously [11] and were maintained as a homozygous colony.
Human CD20-TamCre/MRL/lpr mice were created by
backcrossing human CD20-TamCre/C57BL/6J mice, which
possess an insertion of an IRES-Tam-Cre cassette into the
3′ UTR of the hCD20 locus [12], onto the MRL/lpr back-
ground (Jackson Laboratory, Bar Harbor, Maine) for more
than seven generations. Human CD20-TamCre/MRL/lpr
mice were maintained as heterozygotes via continuous
breeding with MRL/lpr mice (Jackson Laboratory).
Rosa26-Flox-Stop-DTA/MRL/lpr mice were generated by
backcrossing Rosa26-Flox-Stop-DTA/C57BL/6J mice onto
MRL/lpr mice for nine generations [13, 14]. The Rosa26-
Flox-STOP-DTA locus contains a gene for the diphtheria
toxin α chain (DTA), and the expression of the toxin is
inhibited in the presence of the STOP cassette. Rosa26-
Flox-Stop-DTA/MRL/lpr mice were maintained as
homozygotes.Human CD20-TamCre/MRL/lpr and Rosa26-Flox-
Stop-DTA/MRL/lpr mice were crossed to generate the
hCD20-TamCre-Rosa26-DTA/MRL/lpr (hCD20-DTA/
MRL/lpr) mice, a tamoxifen inducible conditional B
cell-depleted strain. To induce B cell depletion,
hCD20-DTA/MRL/lpr mice were treated with intra-
peritoneal tamoxifen (0.2 mg/g weight) every other day
starting at the age of 14 weeks, for five injections in
total. After the last injection, mice were bled the next
day for serum IgG and anti-double stranded DNA IgG
ELISA. After confirming the depletion of antibodies,
animals were allowed to rest for 5 days before neurobe-
havioral testing.
The MRL/MPJ strain (Jackson Laboratory) is a congenic
background control strain for MRL/lpr mice. Unlike
MRL/lpr mice, MRL/MPJ mice carry a normal (unmu-
tated) Fas gene, and therefore do not exhibit a substantial
autoimmune diathesis until a much older age. Since MRL/
MPJ mice are genetically identical to MRL/lpr except in
Fas, it is widely considered the most appropriate control
for the latter lupus strain. At 4 months of age, while MRL/
lpr mice display neuropsychiatric manifestations including
depression-like behavior and cognitive deficits with the
upregulation of inflammatory mediators, MRL/MPJ mice
demonstrate normal emotionality and cognitive function
with baseline brain cytokine expression [15–17].
For all strains employed in these studies, when not all
mice of a particular strain were used for a given experi-
ment, a subset of mice was chosen randomly. All ani-
mals were handled according to the approved animal
protocol at the Albert Einstein College of Medicine.Genotyping
The detailed genotyping procedure for JhD/MRL/lpr mice
by PCR was described previously [18]. For the human
CD20-TamCre/MRL/lpr strain, positive litters were identi-
fied by the presence of Cre and ERT2 genes. The absence
of the Rosa wild-type gene was used to screen for the
Rosa26-Flox-Stop-DTA/MRL/lpr strain. The genotyping
for these two strains was carried out by Transnetyx
(Cordova, TN).Flow cytometry
Peripheral blood was obtained from the hCD20-DTA/
MRL/lpr and JhD/MRL/lpr mice. MRL/lpr mice were
used as positive controls. Blood samples were first lysed
in red blood cell (RBC) lysis buffer and washed with ice-
cold 2 % FBS. B cells were stained with anti-mouse
CD19 conjugated to phycoerythrin (PE) for JhD/MRL/
lpr, or allophycocyanin (APC) (BD Bioscience, San Jose,
CA) for hCD20-DTA/MRL/lpr (the YFP gene in the
latter strain is incompatible with red fluorochromes).
The percentage of CD19 positive cells was gated out of
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(FACScalibur, BD Bioscience).
ELISA
Anti-double stranded (ds) DNA antibodies in the serum
and cerebrospinal fluid (CSF) were measured by ELISA,
as previously described [19]. Total IgG in serum and
CSF was measured by coating the plate with goat anti-
mouse IgG (Southern Biotech, Birmingham, AL) over-
night. Serum and CSF samples at a dilution of 1:500,000
and 1:500, respectively, were added to the plates for 2 h.
Plates were then incubated with alkaline phosphatase-
conjugated goat anti-mouse IgG (Southern Biotech) for
1 h, and developed with phosphatase substrate.
In lupus, the standard method most commonly used to
measure anti-NMDAR antibody titers in both murine
models [15, 20] and human studies [21–23] is by ELISA.
Serum anti-NMDA receptor IgG ELISA was performed by
coating the plate with multimeric peptide DWEYSVWLSN
at 20 μg/ml, as described [15]. Serum samples were added
to the plate at a dilution of 1:250 and detected with alkaline
phosphatase-conjugated goat anti-mouse IgG (Southern
Biotech). It is important, however, to recognize that using
an ELISA-based method for measuring anti-NMDAR anti-
bodies is not a standard neurological practice, and is not
currently recommended for use in the clinical diagnosis of
lupus.
Neurobehavioral testing
Comprehensive behavior testing, including the Porsolt
swim test, open field, object placement, and object rec-
ognition tests, were conducted following the procedures
described previously [19], and further detailed below.
JhD/MRL/lpr mice were tested at 7–12 weeks of age and
CD20-DTA/MRL/lpr mice were tested at 16–18 weeks
of age, with separate age matched controls for each
group. Mice were randomly selected for testing when
not all mice in a given genotype were subjected to a par-
ticular neurobehavioral assessment.
Porsolt swim test
The Porsolt swim test is a standard and validated method
used to evaluate depression-like behavior in rodents. Mice
with depression-like behavior exhibit immobility, an indi-
cation of despair, while normal mice swim for the majority
of the duration of the test. In the Porsolt swim test, each
mouse was placed into a transparent cylindrical tank with
water at 27 °C for 10 min. The first minute was not scored
and in the following 9 min, immobility was scored manu-
ally with stopwatches. Each subject was digitally recorded
using Viewer III software. Total immobility (as % total test
duration) was calculated by the ratio of ([total time immo-
bile in the water]/[total time scored]) × 100. The scorers
were blind to the experimental groups.Open field test
The open field test was conducted in an arena (40 cm×
40 cm× 40 cm) with the center zone defined as 15 cm ×
15 cm. General locomotor activity, including total track
length, center track length, center time, and rears, were re-
corded by Viewer III software (Biobserve, Bonn, Germany)
for 6 min.
Novel object placement and novel object recognition
tests
Object placement (OP) and object recognition (OR) tests
were employed to assess spatial and visual recognition
memory, respectively. In both tests, a training trial (trial
1) and a testing trial (trial 2) were conducted. In the OP
trial 1, animals were given 5 min to explore two identical
objects in different locations. After a 25-min retention
interval, mice were returned to the same arena where
one object was moved to a new location (trial 2). In the
OR trial 1, animals were first allowed to explore two
identical objects for 3 min. After a 90-min retention
interval, animals were tested in the same arena where
one object was replaced with a novel object (trial 2). The
experimenters were blind to the experimental groups.
The preference score (%) for object recognition and ob-
ject placement tests was calculated as ([exploration time
of the novel object (location)]/[exploration time of both
objects (locations)]) × 100. The cutoff to define “pass” in
the object placement and object recognition tests was
53 % [24, 25].
Brain histology
Mice were sacrificed at 19 weeks of age. After extensive
transcardial perfusing with cold PBS, the brains were
dissected into right and left hemispheres. The right
hemisphere of the brain was fixed in 4 % paraformalde-
hyde (PFA) for 24 h at 4 °C, and embedded in paraffin
for sagittal sectioning. The left brain hemisphere includ-
ing the region of the hippocampus was dissected, fixed
in 4 % PFA for 24 h, followed by 30 % sucrose at 4 °C
overnight, and utilized for frozen sections in a coronal
plane. The remaining brain tissue was snap-frozen for
RNA extraction.
Immunofluorescence
For immunofluorescence staining, paraffin sections were
incubated with mouse anti-glial fibrillary acidic protein
(GFAP) (Millipore, Billerica, MA) or rabbit anti-mouse
Iba1 (Chesterfield, VA) antibody, followed by donkey anti-
mouse Alexa Fluor 594 or donkey anti-rabbit Alexa Fluor
488, respectively (Jackson ImmunoResearch, West Grove,
PA). For albumin staining, paraffin sections were directly
incubated with goat anti-mouse albumin-FITC (Alpha
Diagnostic International, San Antonio, TX), and analyzed
under a fluorescence microscope (Zeiss AxioObserver
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brain. Quantitation of the intensity of Iba-1 and GFAP
staining was performed by Image J.TUNEL staining
TUNEL staining was carried out by utilizing an in situ
cell death detection kit-fluorescein (Roche, Indianapolis,
IN) as described previously [26]. Slides were examined
under a fluorescence microscope (Zeiss AxioObserver
CLEM). One representative image was taken from each
section, and the number of TUNEL positive cells in each
section was counted. Two sections were analyzed for
each mouse brain.Real-time PCR
RNA was isolated from the brain of MRL/lpr, JhD/MRL/
lpr, hCD20-DTA/MRL/lpr, and MRL/MPJ mice at
19 weeks of age using RNEASY (Qiagen, Valencia, CA).
Real-time PCR was performed in triplicate for selected
genes including RANTES, MCP-5, IP-10, CXCL11, TNF,
IFNβ, IRF7, and IFIT1 as described [19]. The relative ex-
pression of each gene was normalized to GAPDH, and
the mean relative expression of each gene in the control
group (MRL/MPJ) was set to 1.Statistical analysis
Statistical analysis was performed by Graphpad Prism 6
software. Data are displayed as mean ± standard error of
the mean (SEM). The differences between two groups
were calculated by an unpaired t test (two tailed). Non-
parametric and non-normally distributed data were ana-
lyzed by the Mann-Whitney test. Fisher’s exact test was
employed to compare the incidence of blood-brain bar-
rier leakage between the two groups. Significance was
considered as p < 0.05.Results
B cells, antibodies, and autoantibody levels are negligible
(JhD/MRL/lpr) or significantly reduced (hCD20-DTA MRL/
lpr) in the serum and CSF
To confirm B cell absence or depletion in JhD/MRL/lpr
and hCD20-DTA/MRL/lpr mice, peripheral blood cells
were stained for CD19 by flow cytometry. B cells were
virtually absent in the JhD/MRL/lpr mice (Fig. 1a,
upper right panel). Furthermore, a ~90 % reduction of
B cells was observed in hCD20-DTA/MRL/lpr mice as
compared to MRL/lpr mice (Fig. 1a, lower right panel).
Confirming B cell deficiency in these strains, total IgG
(Fig. 1b), anti-dsDNA IgG (Fig. 1c), and anti-NMDA re-
ceptor IgG (Fig. 1d) antibodies were virtually absent or
significantly reduced in the serum and CSF of JhD/
MRL/lpr and hCD20-DTA/MRL/lpr mice, respectively.JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice demonstrate
depression-like behavior and cognitive dysfunction
One of the distinctive clinical features of human NPSLE
is mood disorder, especially depression [5]. Previously,
we and others reported that MRL/lpr mice display pro-
found depression-like behavior, exhibited by excessive
immobility in the forced swim test as an indicator of be-
havioral despair [19, 27]. To investigate whether this
depression-like behavior is B cell dependent, the Porsolt
swim test was utilized in the B cell-deficient and B cell-
depleted MRL/lpr mouse models. Surprisingly, both
JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice exhibited
markedly increased immobility (50–60 % floating time)
in water as compared to the control MRL/MPJ mice
(15–25 % floating time), and identical to wild-type MRL/
lpr mice (Fig. 2a). Thus, depression-like behavior per-
sisted despite B cell deficiency or depletion in the MRL/
lpr strain.
Cognitive impairment is another common manifest-
ation of NPSLE in both humans and MRL/lpr mice [9].
Autoantibodies such as IgG anti-ribosomal P and anti-
NMDA receptor have been suggested to play a role in
cognitive deficits once the blood-brain barrier (BBB) is
disrupted or circumvented [28, 29]. Thus, we investi-
gated whether B cell-deficient or B cell-depleted lupus
mice, which lack autoantibodies, would demonstrate
cognitive dysfunction using object placement (spatial
memory) and object recognition (visual memory) tests.
Mice preferentially explore novel objects and objects
in novel locations. Thus, a failure to explore novel ob-
jects at greater than chance is an implicit measure of a
failure to retain and/or recall the prior exposure to ei-
ther an object or an object location, respectively, and is
defined as cognitive (memory) impairment. JhD/MRL/
lpr mice manifested spatial memory impairment (Fig. 2b),
while their recognition memory was intact (Fig. 2c). Al-
though hCD20-DTA/MRL/lpr mice trended toward im-
proved spatial memory performance compared to MRL/
lpr mice, the differences did not reach significance
(Fig. 2b, right panel). hCD20-DTA/MRL/lpr mice did,
however, exhibit cognitive deficits in the visual memory
test (Fig. 2c). Our results suggest that, overall, evidence
for cognitive dysfunction was present both for B cell-
deficient or B cell-depleted MRL/lpr mice.
JhD/MRL/lpr mice display increased general locomotion
activity
Open field tests were carried out to assess locomotor
and exploratory activity in B cell-deficient and B cell-
depleted mice. Significantly increased total track length
and number of rears were observed in JhD/MRL/lpr
mice, indicating enhanced motor activity and explor-
ation, respectively (Fig. 3a, b). hCD20-DTA/MRL/lpr
mice, however, displayed behavior similar to MRL/lpr
Fig. 1 (See legend on next page.)
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Fig. 1 B cell counts and antibody titers are markedly reduced in the serum and CSF of JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice. FACS analysis
of CD19 positive cells in the peripheral blood of JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice is shown in (a). The % CD19+ cells is provided in the
red box in each panel. The MRL/lpr strain is used as a positive control. Total IgG levels (b) and anti-dsDNA IgG titers (c) in the serum and CSF of
JhD/MRL/lpr and hCD20/MRL/lpr were measured by ELISA. Anti-NMDA receptor antibodies in the serum of JhD/MRL/lpr and hCD20-DTA/MRL/lpr
mice are shown in (d). (JhD and control mice at 12–15 weeks of age: LPR mice, n = 5–8; JhD mice, n = 5–8; MPJ mice, n = 5–8; hCD20-DTA and
control mice at 15 weeks of age: LPR mice, n = 7; hCD20-DTA mice, n = 7; MPJ mice, n = 7; except for the CSF ELISA experiments, where the number of
mice in the LPR, hCD20-DTA ,and MPJ group were 7, 4, and 4, respectively). The CSF ELISA was done once; all other experiments were repeated twice,
with similar results
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seeking behavior, as measured by the amount of time
spent, or distance travelled, in the center of the testing
arena. Interestingly, MRL/lpr and JhD/MRL/lpr mice
demonstrated an increase in the center track length,
relative center track length (center track length/total track
length), and center time compared to MRL/MPJ mice,
suggesting increased risk-seeking behavior (Fig. 3c–e).
While the relative center track length was unaltered in
hCD20-DTA/MRL/lpr mice compared to MRL/lpr mice
(Fig. 3e), center time was significantly reduced (Fig. 3d).
Thus, JhD/MRL/lpr mice exhibited enhanced overall
motor activity and increased risk-seeking behavior. In
contrast, total locomotion activity was unaltered and
risk-seeking behavior was decreased in hCD20-DTA/
MRL/lpr mice.
JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice exhibit increased
BBB permeability
Disruption of the BBB has been observed in NPSLE pa-
tients, as demonstrated by gadolinium contrast-enhanced
magnetic resonance imaging [30, 31]. Similarly, extravasa-
tion of IgG and other serum proteins into the CNS paren-
chyma was reported in MRL/lpr mice [32]. Here, we
utilized albumin as an indicator of BBB leakage, and found
extravasation of albumin predominantly in the cortex,
periventricular areas, and cerebellum in the JhD/MRL/lpr,
hCD20-DTA/MRL/lpr, and MRL/lpr strains. More than
80 % of mice in each of these strains demonstrated evi-
dence of BBB disruption, as compared to the low base-
line in MRL/MPJ mice (Fig. 4a). Similar results were
obtained by employing immunofluorescent staining of
the brain tissue for fibronectin, another marker for BBB
leakage (data not shown).
hCD20-DTA/MRL/lpr mice display comparable microglial
activation to MRL/lpr
Microglia, as the major phagocytes of the CNS, have an
important role in brain surveillance, as well as in
homeostatic tissue remodeling and synaptic regulation
[33]. With disruption of the BBB, peripheral inflamma-
tory mediators may promote microglial activation. Im-
munofluorescent staining for Iba-1, a marker of
microglial activation, was utilized for the purpose ofexploring microglial activation following constitutive B
cell deficiency or postnatal B cell depletion. Interestingly,
no differences were observed in microglial activation
among MRL/lpr, hCD20-DTA/MRL/lpr, and MRL/MPJ
mice. However, JhD/MRL/lpr mice displayed reduced in-
tensity of Iba-1 staining compared to the other three
strains (Fig. 4b).JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice reveal increased
brain cell apoptosis
Cell apoptosis is one striking feature of the MRL/lpr
mice brains, and is thought to be one of the underlying
causes of the cognitive dysfunction [34, 35]. Thus, we in-
vestigated brain cell apoptosis in B cell-deficient and B
cell-depleted lupus mice by TUNEL staining. The most
common location of TUNEL positive cells in MRL/lpr
mice was the periventricular area, as well as among
the resident epithelial and the locally infiltrating in-
flammatory cells in the choroid plexus (Fig. 5a), but
not in the hippocampus. Although JhD/MRL/lpr mice
possessed significantly fewer TUNEL positive cells
than MRL/lpr mice, these were elevated compared to
MRL/MPJ (Fig. 5a). Surprisingly, hCD20-DTA/MRL/
lpr mice exhibited significantly higher numbers of
TUNEL positive cells, especially in cerebellum, com-
pared to both MRL/lpr and MRL/MPJ mice, perhaps
due to the pro-apoptotic properties of tamoxifen [36]
(Fig. 5a). Thus, brain cell apoptosis was still present in
B cell-deficient and B cell-depleted lupus mice.hCD20-DTA/MRL/lpr mice exhibit hippocampal
astrogliosis
Astrogliosis, referring to astrocyte proliferation in re-
sponse to CNS injury, is increased in the hippocampus
of MRL/lpr mice [37]. To address whether astrocyte pro-
liferation is affected by B cell deficiency, we examined
expression of the astrocyte marker, GFAP, in the brain of
JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice. Upregu-
lated hippocampal astrogliosis was observed in hCD20-
DTA/MRL/lpr mice at a level similar to that found in
MRL/lpr mice, while astrogliosis was less prominent in
JhD/MRL/lpr mice (Fig. 5b).
Fig. 2 JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice display depression-like behavior and cognitive dysfunction. The Porsolt swim test (a) was performed
to evaluate behavioral despair in JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice. (Left panels: LPR mice, n = 10; JhD mice, n = 17; MPJ mice n = 4; Right
panels: LPR mice, n = 7; hCD20-DTA mice, n = 7; MPJ mice, n = 12). Object placement (b) and object recognition (c) tests were employed to assess
cognitive function in JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice. The dotted line indicates 53 % preference score. (Left panels: LPR mice, n = 5; JhD
mice, n = 5; MPJ mice n = 5; Right panels: LPR mice, n = 7; hCD20-DTA mice, n = 7; MPJ mice, n = 10–11). Since testing affects subsequent performance
in neurobehavioral analysis, all behavior tests in a–c were only conducted once. The JhD/MRL/lpr mice were tested at 7–12 weeks of age, and hCD20-
DTA/MRL/lpr mice at 16–18 weeks of age. The control MRL/lpr and MRL/MPJ mice used for comparison were separately age matched to the JhD/
MRL/lpr and hCD20-DTA/MRL/lpr strains, respectively
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brain cytokine expression
Since multiple features of the NPSLE phenotype were pre-
served in JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice,
we investigated the effect of B cell deficiency or depletion
on cytokine expression in the brains of lupus mice. Real-
time qPCR for selected cytokines associated with SLE
and/or NPSLE was carried out, including RANTES, IP-10,MCP-5, CXCL11, and TNF [19, 38–41]. An approximately
two to fourfold suppression in the expression level of
these cytokines was detected in brains of JhD/MRL/lpr
and hCD20-DTA/MRL/lpr in comparison with MRL/lpr
mice (Fig. 6). Nevertheless, RANTES, MCP-5, and IP-10
were still significantly upregulated; as compared to MRL/
MPJ mice, RANTES expression was approximately ten-
fold, and MCP-5 and IP-10 expression approximately
Fig. 3 JhD/MRL/lpr mice exhibit increased general locomotor activity. General locomotor activity was assessed by open field test in JhD/MRL/lpr
at 7–12 weeks of age and hCD20-DTA/MRL/lpr mice at 16 weeks of age including measurement of a total track length, b rears, c center track
length (in cm), d center time (in seconds (s)), and e relative center track length (center track length/total track length). (Left panels: LPR mice, n = 11;
JhD mice, n = 11–12; MPJ mice, n = 5–8; Right panels: LPR mice, n = 7; hCD20-DTA mice, n = 7; MPJ mice, n = 7–17). Open field tests were conducted
once. The control MRL/lpr and MRL/MPJ mice used for comparison were separately age matched to the JhD/MRL/lpr and hCD20-DTA/MRL/lpr
strains, respectively
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and TNF was reduced to baseline levels in B cell-deficient
or B cell-depleted mice (Fig. 6). We also examined the
brain mRNA expression of classic interferon signature
genes, including IFNβ, IRF7, and IFIT1. However, we
found that there were no significant differences in the ex-
pression of any of these three genes among MRL/lpr,
hCD20-DTA, JhD/MRL/lpr, and MRL/MPJ mice (data not
shown). Thus, B cell deficiency or depletion reduced ex-
pression of some inflammatory mediators, but other cyto-
kines were generally still expressed in the brains of JhD/
MRL/lpr and hCD20-DTA/MRL/lpr mice at significantly
higher levels than in the control MRL/MPJ strain.Discussion
In this study, we utilized JhD/MRL/lpr and hCD20-
DTA/MRL/lpr mouse strains to investigate the role of B
cells in the pathogenesis of NPSLE. Autoantibodies and
B cells have either been directly linked or closely associ-
ated with lupus-associated neuropsychiatric manifesta-
tions [4, 42–45]. Evidence supporting the pathogenic
role of autoantibodies can be found in studies which
demonstrated that lupus-derived IgG autoantibodies di-
rected against NMDAR [28], ribosomal P [46], and
phospholipids [47] can induce neurobehavioral deficits,
while in human lupus, the association of autoantibodies
and neuropsychiatric symptoms has also been suggested
Fig. 4 Blood-brain barrier permeability and microglial activation in B cell-deficient and B cell-depleted lupus mice. a Albumin staining was
performed in the brain sections from MRL/lpr (n = 6), JhD/MRL/lpr (n = 4), hCD20-DTA/MRL/lpr (n = 7), and MRL/MPJ (n = 7) mice, all at
19 weeks of age. Representative images of albumin leakage around the vessels (indicated by arrows) in the cortex are shown. Percentages
(%) of mice in each group that are positive for albumin leakage were displayed. Albumin staining was repeated twice, with similar results.
b Iba-1 staining was performed on the brain sections of MRL/lpr (n = 6), JhD/MRL/lpr (n = 4), hCD20-DTA/MRL/lpr (n = 7), and MRL/MPJ (n = 7) mice, all
at 19 weeks of age. Representative images of Iba-1 staining in the cortex are shown. Fold changes of fluorescence intensity are shown in the bottom
panel, with the mean of MRL/MPJ set at 1. Iba-1 staining was repeated twice, with similar results. The scale bar in each image represents 20 μm
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however, we found that B cell deficiency or depletion
does not ameliorate key manifestations of NPSLE, in-
cluding depression-like behavior and cognitive dysfunc-
tion. Our findings therefore strongly suggest that B cells
or circulating antibodies are not strictly required to fully
reproduce the NPSLE phenotype.
Since B cell depletion required testing the mice when
they were no longer young, any potential confounding
effect of age on the behavioral phenotype needs to be
considered. Nevertheless, while the wild-type and B cell-
depleted MRL/lpr mice float excessively (>50 %) at
4 months of age, the age matched control MRL/MPJ
mice displayed minimal floating (~16 %). Indeed, the
lupus mice in our current study floated much more than
older C57BL/6 mice tested previously (historical con-
trols; data not shown). Thus, the reasonable conclusion
would be that age did not significantly affect mobility in
the swim test. Similarly in the other behavior tests as
well, all animals are age matched, and therefore any pos-
sible effects of age were properly controlled for.It is important nevertheless to note that B cell-
deficient or B cell-depleted mice did not always display
the same phenotype. In the neurobehavioral testing,
JhD/MRL/lpr mice exhibited deficient spatial memory
and increased total track length, while the hCD20-DTA/
MRL/lpr displayed abnormal visual memory but pre-
served total track length. Furthermore, histopathological
features characterizing the unmanipulated MRL/lpr
strain including microglial activation, brain cell apop-
tosis, and astrogliosis were more prominent in the
hCD20-DTA/MRL/lpr strain. This divergence can be ex-
plained by the different timing (i.e., congenital depletion)
and relative completeness of B cell depletion (Fig. 1) oc-
curring in the JhD/MRL/lpr strain. Furthermore, even
though the brains from both strains were studied at the
same age, the neurobehavioral assessment of hCD20-
DTA/MRL/lpr was delayed by a few weeks due to
tamoxifen administration. Indeed, some of the pathology
observed in the hCD20-DTA/MRL/lpr strain could have
been induced prior to administration of tamoxifen, or
even after B cell depletion since autoantibodies did not
Fig. 5 Brain cell apoptosis and hippocampal gliosis in JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice. TUNEL and GFAP staining was performed in
MRL/lpr (n = 6), JhD/MRL/lpr (n = 4), hCD20-DTA/MRL/lpr (n = 7), and MRL/MPJ (n = 7) mice, all at 19 weeks of age. Representative images of
TUNEL staining in periventricular areas and choroid plexus are shown in (a, top panels). Quantitation of the average number of TUNEL positive
cells in the two brain sections from each mouse is indicated in the bottom panel. b Representative images of GFAP staining in the hippocampus.
Fold changes of fluorescence intensity are shown in the bottom panel, with the mean of MRL/MPJ set at 1. TUNEL and GFAP staining were repeated
twice, with similar results. The scale bar in each image represents 40 μm
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important features of the neuropsychiatric phenotype of
murine (and human) lupus, including depression-like
behavior (Fig. 2a) and permeabilization of the BBB
(Fig. 4a), persisted despite B cell depletion and did not
differ between the JhD/MRL/lpr and hCD20-DTA/MRL/
lpr strains. We believe that the concurrence of these two
features is not coincidental, as disruption of the neuro-
vascular unit has been linked to non-lupus-related major
depressive disorder as well [48]. Persistence of at least
some of central features of murine NPSLE despite a
marked reduction in, or ablation of, B cells and autoanti-
bodies is an unexpected finding, which we believe is re-
ported here for the first time. Nevertheless, certain
histopathological features did variably improve, and
cytokine expression was attenuated in B cell deficient
mice, indicating that B cells and/or autoantibodies do
affect the brain, albeit not in disrupting the BBB or con-
tributing to depression-like behavior. Furthermore, we
believe that another interesting and potentially revealing
avenue for future studies will indeed be in attempting to
understand the behavioral and pathophysiologic (e.g.,microglial activation, brain cell apoptosis) differences be-
tween lupus mice with constitutive absence of B cells as
compared to those with B cells depleted in later life.
The immune system plays a crucial role in cognition
[49–51]. Microglia, as the major immune cells in the
brain, function as phagocytes to clear cell debris and
maintain surveillance and homeostasis in the central
nervous system. Microglia, together with T cells, are im-
plicated in hippocampal neurogenesis and spatial mem-
ory [52, 53]. Mice deprived of mature T cells displayed
impaired hippocampal neurogenesis and cognitive dys-
function, which can be reversed by restoring T cells that
recognized a specific brain antigen [53]. Furthermore,
antibodies have been shown to affect brain growth and
development [54]. Thus, although we are not aware of
any direct evidence defining the role of endogenous B
cells during development on cognition, these cells can
possibly influence future cognitive function, either dir-
ectly or through their interaction with other immune
cells. We speculate that this might be one possible cause
for the partial dependence of the neurobehavioral
phenotype on the timing of B cell depletion.
Fig. 6 Cytokine expression in the brain of B cell-deficient and B cell-depleted lupus mice. Real-time PCR was performed on the brain RNA samples,
extracted from randomly selected MRL/lpr (n = 6), JhD/MRL/lpr (n = 4), hCD20-DTA/MRL/lpr (n = 7), and MRL/MPJ (n = 7) mice, all at 19 weeks of age.
Fold changes of each gene were calculated and normalized to the mean of each gene in MRL/MPJ group, which was set at 1. Real-time PCR was
repeated twice, with similar results
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NPSLE has yet to be fully clarified. Multiple brain react-
ive and non-brain specific antibodies are associated with
NPSLE [6]. Anti-cardiolipin autoantibodies and lupus
anticoagulant in particular have been strongly associated
with cerebrovascular disease; anti-ribosomal P antibodies
correlate with lupus psychosis, and anti-NMDA receptor
antibodies have been associated with diffuse NPSLE
manifestations [55]. This diversity in autoantibody speci-
ficities associated with NPSLE may represent the varied
and complex nature of NPSLE manifestations, which
plausibly can be related to multiple different autoanti-
bodies. However, although some encouraging results
were observed in clinical trials of NPSLE patients with
the B cell-depleting therapy rituximab [56, 57], these
studies only included a relatively small number ofpatients and were uncontrolled. Thus, the efficacy of ri-
tuximab as a therapeutic approach for NPSLE patients
remains to be determined [57].
In murine models, several studies have demonstrated
that autoantibodies can bind to brain specific antigens,
inducing lupus-like pathologic behavior. Katzav et al.
found that anti-ribosomal P antibodies deposited in the
limbic system (piriform cortex, hippocampus, and cingu-
late cortex) can produce depression-like behavior [46].
Similarly, a recent study showed that anti-ribosomal P
antibodies purified from NPSLE patients bound to hip-
pocampal neurons in the brains of healthy mice, leading
to memory impairment [29]. Moreover, Kowal et al.
demonstrated that following compromise of the BBB,
anti-NMDA receptor antibodies can induce neuronal
cell death resulting in cognitive dysfunction [28].
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CA1 region of the hippocampus [28]. Nevertheless, to
our surprise, we found that B cell-deficient and B cell-
depleted MRL/lpr mice continued to exhibit features of
the characteristic NPSLE phenotype of this strain. Both
JhD/MRL/lpr and hCD20-DTA/MRL/lpr mice demon-
strated depression-like behavior and cognitive deficits
similar to unmanipulated MRL/lpr mice, as well as BBB
disruption, brain cell apoptosis, and cytokine upregula-
tion. This observation can be explained in several ways.
First, although the abrogation of BBB may indeed be a
prerequisite for autoantibodies to access the brain, the
opening of BBB is usually transient, and eventually, the
autoantibodies that bypass the BBB play a less important
role in disease initiation than other inflammatory media-
tors within the CNS. Second, the strains of mice were
different; autoimmune MRL/lpr mice (a strain with spon-
taneous disease and thus more similar to human SLE) are
characterized by a complex dysregulation of cytokines
and antibodies, while previous studies addressing the
role of pathogenic antibodies in murine NPSLE used
non-autoimmune strains, and tested whether manipula-
tions elicited acute behavioral or histologic alterations.
We found that disruption of the BBB persisted despite
acute B cell deficiency or depletion. This breached BBB can
trigger an inflammatory cascade, modulating astrocyte-
neuron crosstalk and altering the release of neurotransmit-
ters, which may have contributed to the observed
behavioral abnormalities. Increased brain cell apoptosis
among JhD/MRL/lpr, hCD20-DTA/MRL/lpr, and MRL/lpr
mice may be another consequence of BBB disruption.
While the more marked apoptosis observed in the hCD20-
DTA as compared to the JhD/MRL/lpr strain may have
been contributed by tamoxifen [36], the fact that both
MRL/lpr and to a lesser degree JhD/MRL/lpr had signifi-
cantly increased brain cell apoptosis as compared to the
MRL/MPJ mice suggests that this process is a characteristic
of (if not a contributor to) NPSLE in this strain, which is
not eliminated by a reduction in the numbers of B cells.
The role of cytokines in NPSLE is supported by nu-
merous studies. Although SLE is characterized by high
titers of autoantibodies, the onset of NPSLE can occur at
any stage of the disease, even prior to a significant rise
in autoantibody titers [15]. Furthermore, the severity of
NPSLE may not correlate with autoantibody titers [58].
MRL/lpr mice develop depression-like behavior before
the peak of autoantibody production or evidence of
systemic disease [19]. Cytokine dysregulation, however,
occurs as early as 1–4 weeks of age [59–62]. We found
decreased expression of RANTES, MCP-5, IP-10, CXCL11,
and TNF following B cell deficiency or depletion in MRL/
lpr mice. Nevertheless, at least RANTES, MCP-5, and IP-
10 remained significantly elevated in B cell-deficient and B
cell-depleted mice in comparison with MRL/MPJ mice.This observation suggests that these cytokines (or others
not tested for), probably derived from CNS resident cells
such as astrocytes and microglia, may actually be the key
effectors in initiating the pathogenesis of NPSLE—at least
in the absence of B cells and/or autoantibodies. This
observation is consistent with several clinical studies
that found that increased levels of RANTES, IP-10, and
MCP-5 in the CSF correlate with NPSLE manifestations
[38–41]. Furthermore, the persistence of the NPSLE
phenotype in JhD/MRL/lpr and hCD20-DTA/MRL/lpr
mice may indicate that mood and cognition are very
sensitive to cytokine abnormalities, and therefore, a ro-
bust NPSLE phenotype is manifested even with lower
brain cytokine levels than in the MRL/lpr strain.
Besides the role cytokines play in CNS abnormalities,
other potential contributors may also need to be taken
into consideration. Long-lived plasma cells secreting
autoantibodies are resistant to B cell depletion [10];
however, these would be absent in the B cell-deficient
strain (JhD/MRL/lpr), and thus, these plasma cells are un-
likely to be the early mediators of NPSLE. Additionally,
Chan et al. reported that although tenfold reductions in
CD4+ and CD8+ T cells were observed in B cell-deficient
mice (JhD/MRL/lpr), a few T cells were persistent [18],
suggesting a potential role for T cells as well. Furthermore,
gut microbiota has recently been suggested to be involved
in brain function including anxiety, mood, cognition, and
pain [63]. Therefore, whether B cell deficiency or deple-
tion modulates gut microbiota will be an interesting ques-
tion to explore. Finally, Fas and Fas ligand are expressed
in the CNS, and one may ask whether the neuropsychi-
atric symptoms seen in MRL/lpr mice are mediated by ab-
normal Fas signaling [64], for example, by altering
apoptosis in microglia and/or other brain cell types.
Nevertheless, since NPSLE manifestations also appear in
other, non-Fas-mediated murine lupus models [9], auto-
immunity is the most likely mechanistic explanation in
the MRL/lpr model as well.
Thus, there are several potential mechanisms to explain
the persistence of neuropsychiatric lupus in MRL/lpr mice
despite a significant decrease in, or depletion of, B cells
and autoantibodies, including pathways involving cyto-
kines, microglial activation, neurotransmitters, etc. We ac-
knowledge that while the differential effects on cytokines
reported above are interesting, these studies are prelimin-
ary. Moreover, the additional possible mechanisms will
need to be further explored. Indeed, considering the com-
plex immune abnormalities present in SLE, we believe
that the neurobehavioral deficits seen in murine lupus
strains (and in human disease) are most likely due to the
combined contributions of more than a single mechan-
ism. The lack of strict dependence of neuropsychiatric
lupus on the presence of B cells and autoantibodies is
nonetheless a novel and surprising observation, and
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study will be required in the future to continue to define
the relevant molecular pathways.
Conclusions
Our data collectively indicate that lack of B cells and auto-
antibodies in MRL/lpr mice does not prevent the develop-
ment of key features of NPSLE; this is most convincingly
shown by the neurobehavioral deficits observed in JhD/
MRL/lpr mice that lacked B cells from birth. Furthermore,
among the cytokines studied, we found that RANTES, IP-
10, and MCP-5 were persistently elevated in B cell-deficient
and B cell-depleted MRL/lpr mice, suggesting a possible
role as effectors of NPSLE pathogenesis. Future studies can
include a more comprehensive characterization of the cyto-
kines produced in B cell-deficient and B cell-depleted mice
and identification of their cellular origins within the CNS,
and further exploration of the contribution of T cells and
microbiota. It will be interesting to test whether intracere-
bral cytokine administration alone can induce a NPSLE-like
phenotype. If in fact that is the case, such a mediator may
provide a valuable therapeutic target for this challenging
lupus end-organ manifestation.
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